⭐️Ethics of placebo-controlled trials in PsA ➡️move toward active comparator designs. Need to use measures of deeper response (e.g., ACR 50, PASI100). ⭐️Assesing safety: LTE studies not adequate. Use of phase 4 studies or observational data but beware confounding by indication